Treatment significantly prolonged the survival of tumor-bearing mice, suggesting that CLDN3 and CLDN4 may represent promising therapeutic targets for the management of aggressive, treatment-resistant type II endometrial cancers. Here, CLDN4 is linked to neoplasm.